Entegrion to develop dehydrated blood products for U.S. Navy

08/7/2009 | American City Business Journals

The U.S. Navy has awarded two contracts worth $4 million to Entegrion for the development of blood-derived products. The first contract is for the development of Stasix, a powder containing dehydrated particles taken from human blood platelets that can be easily rehydrated and administered to halt a person's internal or external bleeding. The second is for the development of the firm's Resusix, a dehydrated human plasma product with decreased pathogens that is designed for infusion in patients to increase blood volume, treat blood clotting inconsistencies and stop bleeding.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC